Objectives: ACHIEVE-ONE is a large-scale clinical study designed to evaluate the effects of cilnidipine, a unique L/N-type Ca channel blocker, on blood pressure (BP) measured at the clinic, home, and by ambulatory BP monitoring (ABPM) in Japanese hypertensive patients. We searched a potential morning surge which could be detected only by ABPM, but not self-measured BP monitoring at home. Design and Methods: We analyzed 378-patient data that obtained both self-measured home systolic BP (SBP) at wake-up (SBPself-w) and 2-hour average SBP after wake-up by ABPM (SBPabpm-w). The sleep-trough morning surge (ST-MS) was defined as difference between SBPabpm-w and the lowest 1-hour moving average SBP during sleep period. The top decile of ST-MS and the remaining 90% were subclassified as ST-MS Group and Non-ST-MS Group, respectively. The difference between SBPabpm-w and SBPself-w was defined as ambulatory morning surge (AMS). Results: SBPabpm-w (170.4 ± 15.2 mmHg) was significantly higher than SBPself-w (154.7 ± 17.7 mmHg) in ST-MS Group (n = 38, ≥53.5 mmHg), while there was no difference in SBPself-w between ST-MS Group and Non-ST-MS Group. The ambulatory SBP in ST-MS Group reached a peak at 1-2 hour after wake-up (Fig.1). The AMS was greater in ST-MS Group (15.6 ± 16.2 mmHg) than in Non-ST-MS Group (-1.9 ± 18.4 mmHg). 12-week treatment of cilnidipine reduced SBPabpm-w and SBPself-w in ST-MS Group. Conclusions: Self-measured morning home BP may underscore the risk of morning surge. The ambulatory morning surge, newly defined by combination of ABPM and home BP monitoring, may explain the cardiovascular risk of morning BP surge.